【爱博医疗签订《 查找图书 》】 【标的主营业务】 标的公司：德美医疗 定位：专注"运动医学+运动健康"的科技型企业 业务链条：覆盖「术前预防—手术治疗—术后康复」全链条 产品/业务范围（集团一体化）： 1）运动医学植入物 2）手术工具 3）关节镜设备 【爱博医疗签订《 查找图书 》】 【标的主营业务】 标的公司：德美医疗 定位：专注"运动医学+运动健康"的科技型企业 业务链条：覆盖「术前预防—手术治疗—术后康复」全链条 产品/业务范围（集团一体化）： 1）运动医学植入物 2）手术工具 3）关节镜设备 4）运动康复器具和设备 5）研发/生产/销售/服务 行业地位：国内行业头部企业 集采资质：已入选国家高值医用耗材集采A组 【收购估值及比例】 对标的公司整体估值：预计不超过人民币10亿元 最终交易价格：以资产评估报告+尽调结果为准，协商确定 收购比例：不低于51%股权 收购目标：取得标的公司控制权 【近三年财务情况】 营业收入（持续增长）： 2023年：1.78亿元 2024年：2.36亿元 2025年：2.86亿元 净利润（调整后）： 2023年：亏损707.82万元 2024年：盈利929.37万元 202 ...

Core Viewpoint - Aibo Medical announced plans to acquire at least 51% of Demai Medical, with an estimated valuation of the target company not exceeding 1 billion yuan [1] Company Summary - Demai Medical, founded in July 2016, has a registered capital of over 12.14 million yuan and is controlled by its founder and major shareholder, Li Jianbo, who holds 14.7994% of the shares [1] - The company has a strategic focus on the entire spectrum of sports health, including pre-surgery prevention, surgical treatment, and post-surgery rehabilitation, and operates as an international medical technology group [1][2] - As of the announcement date, Demai Medical has 276 authorized patents and has obtained various medical device registrations, including 34 Class III, 48 Class II, and 63 Class I medical device registration certificates [2] Industry Summary - The domestic sports medicine market is currently dominated by international brands, which hold approximately 80% market share, with major players including Stryker, Johnson & Johnson, and Arthrex [5] - The market size for sports medicine in China is projected to reach 8-10 billion yuan in 2025, with a compound annual growth rate of about 15%-20% [5] - The inclusion of sports-related injury implants in the national procurement plan in 2024 is expected to create opportunities for domestic companies to expand their market share and enhance industry influence [2] Financial Summary - As of the end of 2025, Demai Medical's total assets are projected to be 425 million yuan, with total liabilities of 160 million yuan and equity of 260 million yuan [3] - The expected revenue for 2025 is 286 million yuan, with an adjusted net profit of approximately 35.02 million yuan [3]